UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 1998
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Commission file number: 0-15006
AVANT IMMUNOTHERAPEUTICS, INC.
(f/k/a T Cell Sciences, Inc.)
(Exact name of registrant as specified in charter)
Delaware No. 13-3191702
(State of Incorporation) (I.R.S. Employer Identification No.)
119 Fourth Avenue, Needham, Massachusetts 02494-2725
(Address of principal executive offices) (Zip code)
(781) 433-0771
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days. Yes X No .
--- ---
Outstanding as of
Class November 10, 1998
----- -----------------
Common Stock, par value $.001 42,507,269
1
<PAGE>
AVANT IMMUNOTHERAPEUTICS, INC.
Table of Contents
September 30, 1998
<TABLE>
<CAPTION>
Page
----
<S> <C>
Part I -- Financial Information
- - -------------------------------
Condensed Consolidated Balance Sheet at September 30, 1998 and December 31, 1997........................3
Condensed Consolidated Statement of Operations for the Quarters Ended
September 30, 1998 and 1997....................................................................4
Condensed Consolidated Statement of Operations for the Nine months Ended
September 30, 1998 and 1997....................................................................5
Condensed Consolidated Statement of Cash Flows for the Nine months Ended
September 30, 1998 and 1997....................................................................6
Notes to Condensed Consolidated Financial Statements....................................................7
Management's Discussion and Analysis of Financial Condition and Results of
Operations...........................................................................................10
Part II -- Other Information
- - ----------------------------
Item 1. Legal Proceedings.............................................................................13
Item 2. Changes in Securities.........................................................................13
Item 3. Defaults Upon Senior Securities...............................................................13
Item 4. Submission of Matters to a Vote of Security Holders...........................................13
Item 5. Other Information.............................................................................13
Item 6. Exhibits and Reports on Form 8-K
A. Exhibits..................................................................................13
B. Reports on Form 8-K.......................................................................14
Signatures.............................................................................................15
</TABLE>
2
<PAGE>
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
--------------------
AVANT IMMUNOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
September 30, 1998 and December 31, 1997
<TABLE>
<CAPTION>
September 30, December 31,
1998 1997
===============================================================================================================
<S> <C> <C>
ASSETS (audited)
Current Assets:
Cash and Cash Equivalents $ 7,150,500 $ 6,436,300
Marketable Securities 7,865,300 --
Current Portion Restricted Cash 750,000 750,000
Accounts Receivable 10,600 22,900
Inventories 9,200 15,000
Prepaid Expenses and Other 532,200 165,400
- - ---------------------------------------------------------------------------------------------------------------
Total Current Assets 16,317,800 7,389,600
- - ---------------------------------------------------------------------------------------------------------------
Property and Equipment, Net 1,066,000 364,500
Restricted Cash 1,195,000 525,000
Goodwill 3,985,000 --
Other Noncurrent Assets 2,582,700 1,547,500
- - ---------------------------------------------------------------------------------------------------------------
Total Assets $25,146,500 $ 9,826,600
===============================================================================================================
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts Payable $ 225,200 $ 201,200
Accrued Expenses 1,780,000 1,059,900
Deferred Revenue -- 750,000
Short-Term Note Payable 750,000 750,000
- - ---------------------------------------------------------------------------------------------------------------
Total Current Liabilities 2,755,200 2,761,100
- - ---------------------------------------------------------------------------------------------------------------
Long-Term Note Payable 750,000 750,000
Other Long-Term Liabilities 588,600 --
Stockholders' Equity:
Common Stock, $.001 Par Value 42,500 26,500
Additional Paid-in Capital 140,744,600 76,561,400
Less: Common Treasury Shares at Cost (13,700) (35,800)
Accumulated Deficit (119,720,700) (70,236,600)
- - ---------------------------------------------------------------------------------------------------------------
Total Stockholders' Equity 21,052,700 6,315,500
- - ---------------------------------------------------------------------------------------------------------------
Total Liabilities and Stockholders' Equity $25,146,500 $ 9,826,600
===============================================================================================================
</TABLE>
See accompanying notes to condensed consolidated financial statements
3
<PAGE>
AVANT IMMUNOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
For the Quarters Ended September 30, 1998 and 1997
<TABLE>
<CAPTION>
September 30, September 30,
1998 1997
===============================================================================================================
<S> <C> <C>
OPERATING REVENUE:
Product Development and Licensing Agreements $ 401,800 $ 48,500
Product Sales 9,500 34,900
- - ---------------------------------------------------------------------------------------------------------------
Total Operating Revenue 411,300 83,400
- - ---------------------------------------------------------------------------------------------------------------
OPERATING EXPENSE:
Cost of Product Sales 2,600 16,800
Research and Development 1,810,400 1,269,700
Charge for Purchased In-Process Research and 44,630,000 --
Development
General and Administrative 880,400 855,000
- - ---------------------------------------------------------------------------------------------------------------
Total Operating Expenses 47,323,400 2,141,500
- - ---------------------------------------------------------------------------------------------------------------
Operating Loss (46,912,100) (2,058,100)
Non-Operating Income (Expense), Net 144,000 (5,972,100)
- - ---------------------------------------------------------------------------------------------------------------
Net Loss $(46,768,100) $(8,030,200)
===============================================================================================================
Net Loss Per Common Share $(1.35) $ (0.32)
===============================================================================================================
Weighted Average Common Shares Outstanding 34,722,000 24,955,700
===============================================================================================================
</TABLE>
See accompanying notes to condensed consolidated financial statements
4
<PAGE>
AVANT IMMUNOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
For the Nine months Ended September 30, 1998 and 1997
<TABLE>
<CAPTION>
September 30, September 30,
1998 1997
====================================================================================================
<S> <C> <C>
OPERATING REVENUE:
Product Development and Licensing Agreements $ 1,037,700 $ 803,900
Product Sales 44,500 36,200
- - ----------------------------------------------------------------------------------------------------
Total Operating Revenue 1,082,200 840,100
- - ----------------------------------------------------------------------------------------------------
OPERATING EXPENSE:
Cost of Product Sales 20,500 17,200
Research and Development 4,070,200 4,088,600
Charge for Purchased In-Process Research and
Development 44,630,000 --
General and Administrative 2,385,200 2,724,600
- - ----------------------------------------------------------------------------------------------------
Total Operating Expenses 51,105,900 6,830,400
- - ----------------------------------------------------------------------------------------------------
Operating Loss (50,023,700) (5,990,300)
Non-Operating Income (Expense), Net 539,600 (5,656,300)
- - ----------------------------------------------------------------------------------------------------
Net Loss $(49,484,100) $(11,646,600)
====================================================================================================
Net Loss Per Common Share $(1.65) $ (0.47)
====================================================================================================
Weighted Average Common Shares Outstanding 30,025,900 24,950,800
====================================================================================================
</TABLE>
See accompanying notes to condensed consolidated financial statements
5
<PAGE>
AVANT IMMUNOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
For the Nine months Ended September 30, 1998 and 1997
<TABLE>
<CAPTION>
September 30, September 30,
1998 1997
===============================================================================================================
<S> <C> <C>
Cash Flows from Operating Activities:
Net Loss $(49,484,100) $(11,646,600)
Adjustments to Reconcile Net Loss to Net Cash
Used by Operating Activities:
Depreciation and Amortization 428,800 272,300
Write-off of Capitalized Patent Costs 12,300 51,100
Gain on Sale of Equipment (20,000) --
Returned Stock (165,600) --
Settlement of Litigation with Former Landlord -- 6,109,200
Charge for Purchased In-Process Research and
Development 44,630,000 --
Net Change in Current Assets and Current
Liabilities (3,223,600) (409,600)
- - ---------------------------------------------------------------------------------------------------------------
Net Cash Used by Operating Activities (7,822,200) (5,623,600)
- - ---------------------------------------------------------------------------------------------------------------
Cash Flows from Investing Activities:
Acquisition of Property and Equipment (149,200) (70,300)
Proceeds from the Sale of Equipment 23,000 --
Redemption of Marketable Securities 1,500,700 --
Other Noncurrent Assets (281,100) (175,100)
Increase in Long-Term Restricted Cash (670,000) --
Net of Cash Received from Purchase of Virus
Research Institute, Inc. 4,391,500 --
Sale of Investment in Common Stock of
Endogen, Inc. -- 1,802,700
- - ---------------------------------------------------------------------------------------------------------------
Net Cash Provided by Investing Activities 4,814,900 1,557,300
- - ---------------------------------------------------------------------------------------------------------------
Cash Flows from Financing Activities:
Proceeds from the Exercise of Stock Options 10,300 --
Proceeds from the Issuance of Common Stock 3,699,900 --
Proceeds from Sale of Stock 11,300 12,500
- - ---------------------------------------------------------------------------------------------------------------
Net Cash Provided by Financing Activities 3,721,500 12,500
- - ---------------------------------------------------------------------------------------------------------------
Increase (Decrease) in Cash and Cash Equivalents 714,200 (4,053,800)
Cash and Cash Equivalents at Beginning of Period 6,436,300 12,591,800
- - ---------------------------------------------------------------------------------------------------------------
Cash and Cash Equivalents at End of Period $ 7,150,500 $ 8,538,000
===============================================================================================================
Supplemental Cash Flow Information
Non-cash Investing Activities:
Securities Issued for Acquisition
of Virus Research Institute, Inc. (See Note 3) $60,665,500 --
</TABLE>
See accompanying notes to condensed consolidated financial statements
6
<PAGE>
AVANT IMMUNOTHERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements
September 30, 1998
(1) Nature of Business
AVANT Immunotherapeutics, Inc. ("AVANT" or the "Company") is a
biopharmaceutical company engaged in the discovery, development and
commercialization of products that harness the human immune response to prevent
and treat disease. The Company's lead therapeutic program is focused on
compounds that inhibit the inappropriate activity of the complement cascade
which is a vital part of the body's immune defense system. The Company is also
engaged in the development of Therapore(TM), a novel system for the delivery of
immunotherapeutics for chronic viral infections and certain cancers. The Company
and its collaborators are developing vaccines using the proprietary adjuvants,
Adjumer(TM) and Micromer(TM), for the prevention of influenza, Lyme disease, and
respiratory syncytial virus (RSV). In a further collaboration, the Company is
developing an oral human rotavirus vaccine, and is developing its own
proprietary vaccine for the management of atherosclerosis.
The condensed consolidated financial statements include the accounts of
AVANT Immunotherapeutics, Inc. and its wholly owned subsidiaries, Virus Research
Institute, Inc. ("VRI"), from the date of purchase (see Note 3), and T Cell
Diagnostics, Inc. All intercompany transactions have been eliminated.
(2) Interim Financial Statements
The accompanying condensed consolidated financial statements for the
three and nine months ended September 30, 1998 and 1997 include the consolidated
accounts of the Company, and have been prepared in accordance with generally
accepted accounting principles and with the instructions to Form 10-Q and
Article 10 of Regulation S-X. In the opinion of management, the information
contained herein reflects all adjustments, consisting solely of normal recurring
adjustments, that are necessary to present fairly the financial positions at
September 30, 1998 and December 31, 1997, the results of operations for the
quarters and nine months ended September 30, 1998 and 1997, and the cash flows
for the nine months ended September 30, 1998 and 1997. The results of operations
for the quarter and nine months ended September 30, 1998 are not necessarily
indicative of results for any future interim period or for the full year.
Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been omitted, although the Company believes that the disclosures
included are adequate to make the information presented not misleading. The
condensed consolidated financial statements and the notes included herein should
be read in conjunction with footnotes contained in the Company's Annual Report
on Form 10-K for the year ended December 31, 1997.
(3) Acquisition of Virus Research Institute, Inc.
On August 21, 1998, the Company acquired all of the outstanding capital
stock of VRI, a company engaged in the discovery and development of (i) systems
for the delivery of vaccines and immunotherapeutics and (ii) novel vaccines. The
Company issued approximately 14,036,400 shares of AVANT common stock and
warrants to purchase approximately 1,811,200 shares of AVANT common stock in
exchange for all of the outstanding common stock of VRI, on the basis of 1.55
shares of AVANT's common stock and .20 of an AVANT warrant for one share of VRI
common stock. The purchase price of $63,286,100 consisted of (i) the issuance of
14,036,400 shares of AVANT common stock valued at $51,686,700 and 1,811,200
AVANT warrants valued at $4,980,700 for all outstanding VRI capital stock, (ii)
the issuance of AVANT warrants
7
<PAGE>
valued at $387,700 in exchange for all of the outstanding VRI warrants, (iii)
the issuance of options to purchase AVANT common stock valued at $3,610,400 for
all of the outstanding options to purchase VRI common stock assumed by the
Company, and (iv) severance and transaction costs totaling $2,620,600.
The allocation of the purchase price was determined as follows:
<TABLE>
<S> <C>
Net tangible assets acquired $ 14,538,100
Intangible assets acquired:
Work force 470,000
Collaborative relationships 1,090,000
Goodwill 2,558,000
In-process technology 44,630,000
----------
Total $ 63,286,100
==========
</TABLE>
The acquisition has been accounted for as a purchase, and accordingly,
the original purchase price was allocated to acquired assets and assumed
liabilities based upon their fair value at the date of acquisition. The purchase
price has been allocated to assets acquired and to in-process research and
development which has been charged as an expense in the AVANT consolidated
financial statements for the three and nine months ended September 30, 1998.
Intangibles arising from the acquisition are being amortized on a straight line
basis over 36 months and 60 months. The operating results of VRI from August 22,
1998 to September 30, 1998 have been included in the Company's consolidated
results of operations.
The following unaudited pro forma financial summary is presented as if
the operations of the Company and VRI were combined as of January 1, 1998 and
1997, respectively. The unaudited pro forma combined results are not necessarily
indicative of the actual results that would have occurred had the acquisition
been consummated at that date, or of the future operations of the combined
entities. Nonrecurring charges, such as the acquired in-process research and
development charge of $44,630,000, are not reflected in the following pro forma
financial summary.
<TABLE>
<CAPTION>
Nine Months Ended
September 30,
-----------------------------------------
1998 1997
------------- --------------
<S> <C> <C>
Operating Revenue $ 1,138,300 $ 2,617,300
Net Loss $ (11,121,010) $ (18,305,600)
Basic and diluted net loss per share $ (0.27) $ (0.47)
</TABLE>
(4) Issuance of Common Stock
In March 1998, the Company completed a private placement of
approximately 2,043,000 shares of common stock to institutional investors at a
price of $1.90 per share. Net proceeds from the common stock issuance totaled
approximately $3,699,900. The Company believes that its current cash, cash
equivalents and marketable securities, which includes the private placement
proceeds, together with cash flows from existing SBIR grants and collaborations
and interest income on invested funds, will be sufficient to meet working
capital requirements and fund operations into 2000. The working capital
requirements will depend on several factors including, but not limited to, the
progress and costs associated with research and development programs,
preclinical and clinical studies, and the timing and scope of collaborative
arrangements.
8
<PAGE>
(5) Statement of Financial Accounting Standards Nos. 130, 131 and 133
In June 1997, the Financial Accounting Standards Board issued Statement
of Accounting Standards Nos. 130, "Reporting Comprehensive Income" ("SFAS 130"),
and 131, "Disclosures about Segments of an Enterprise and Related Information"
("SFAS 131") to become effective for interim and annual periods beginning after
December 15, 1997. The Company adopted SFAS 130 and SFAS 131 on January 1, 1998.
SFAS 130 establishes standards for the reporting of comprehensive income and its
components in the consolidated financial statements. To date the Company has not
had material adjustments between net income as reported and comprehensive income
as defined by SFAS 130. SFAS 131 establishes standards for the reporting of
information on operating segments in interim and annual financial statements
beginning with the annual financial statements for the year ending December 31,
1998.
In June 1998, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards No. 133, Accounting for Derivative Instruments
and Hedging Activities (FAS 133). FAS 133 is effective for all fiscal quarters
of all fiscal years beginning after June 15, 1999 (January 1, 2000 for the
Company). FAS 133 requires that all derivative instruments be recorded on the
balance sheet at their fair value. Changes in the fair value of derivatives are
recorded each period in current earnings or other comprehensive income,
depending on whether a derivative is designated as part of a hedge transaction
and, if it is, the type of hedge transaction. Management of the Company
anticipates that, due to its limited use of derivative instruments, the adoption
of FAS 133 will not have a significant effect on the Company's results of
operations or its financial position.
9
<PAGE>
Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: The following, Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, includes forward-looking statements which
reflect AVANT's current views with respect to future events and financial
performance. The words "believe,' "expect,' "anticipate," and similar
expressions identify forward-looking statements. Investors should not rely on
forward-looking statements because they are subject to a variety of risks,
uncertainties, and other factors that could cause actual results to differ
materially from those expressed in any such forward-looking statements. These
factors include, but are not limited to: (1) the ability to successfully
complete development and commercialization of products, including the scope and
results of preclinical and clinical testing; (2) the ability to successfully
complete product research and further development including animal, pre-clinical
and clinical studies; (3) changes in existing and potential relationships with
corporate collaborators; (4) the time, cost and uncertainty of obtaining
regulatory approvals; (5) the ability to obtain substantial additional funding;
(6) the ability to develop and commercialize products before competitors; and
(7) other factors detailed from time to time in filings with the Securities and
Exchange Commission.
Item 2. Management's Discussion And Analysis Of Financial Condition And
Results Of Operations
----------------------------------------------------------------
Overview
AVANT Immunotherapeutics, Inc. is a biopharmaceutical company engaged
in the discovery, development and commercialization of products that harness the
human immune response to prevent and treat disease. The Company's lead
therapeutic program is focused on compounds that inhibit the inappropriate
activity of the complement cascade which is a vital part of the body's immune
defense system. The Company is also engaged in the development of Therapore(TM),
a novel system for the delivery of immunotherapeutics for chronic viral
infections and certain cancers. The Company and its collaborators are developing
vaccines using the proprietary adjuvants, Adjumer(TM) and Micromer(TM), for the
prevention of influenza, Lyme disease, and respiratory syncytial virus (RSV). In
a further collaboration, the Company is developing an oral human rotavirus
vaccine, and is developing its own proprietary vaccine for the management of
atherosclerosis.
Results of Operations
Quarter Ended September 30, 1998 Compared to Quarter Ended September
30, 1997 -- The Company reported a net loss of $46,768,100, or $1.35 per share,
for the third quarter ended September 30, 1998, compared to a net loss of
$8,030,200, or $.32 per share, for the third quarter ended September 30, 1997.
The net operating loss for the third quarter of 1998, which included a charge of
$44,630,000 for in-process research and development related to the acquisition
of Virus Research Institute, Inc. ("VRI"), was $46,912,100. Excluding the
in-process and development charge, the net operating loss for the third quarter
of 1998 would have been $2,282,100, an increase of $224,000, or 10.9%, compared
to net operating loss of $2,058,100 for the same period last year.
Operating revenue of $411,300 for the third quarter of 1998 increased
$327,900, or 393.2% compared to $83,400 for the third quarter of 1997. Product
development and licensing agreements revenue of $401,800 increased $353,300 or
728.5% for the third quarter of 1998 compared to $48,500 for the same period
last year. The increase is primarily due to $250,000 recognized in the third
quarter of 1998 from a nonrefundable option fee associated with the Company's
agreement with Novartis Pharma AG which is being recognized over the option term
combined with $151,800 received in connection with the Company's Small Business
Innovation Research ("SBIR") grants during the third quarter of 1998. Revenue
during the third quarter of 1997 consisted of $48,500 received in connection
with the Company's SBIR grants. Product sales were $9,500 for the quarter ended
September 30, 1998 compared to product sales of $34,900 for the quarter ended
September 30, 1997.
Operating expense of $47,323,400 for the third quarter of 1998 included
a charge of $44,630,000 for in-process research and development related to the
acquisition of VRI. Excluding the in-process
10
<PAGE>
research and development charge, operating expense for the third quarter of 1998
increased $551,900, or 25.8%, to $2,693,400 for the quarter ended September 30,
1998 compared to $2,141,500 for the quarter ended September 30, 1997. The
increase in operating expense is primarily due to a $540,700 increase in
research and development expense combined with a $25,400 increase in general and
administrative expense for the quarter compared to the same period last year.
For the third quarter of 1998 research and development expense increased 42.6%
to $1,810,400 compared to $1,269,700 for the third quarter of 1997 primarily due
to the acquisition of VRI on August 21, 1998. This was partially offset by costs
associated with ongoing clinical trials in 1997 compared to no clinical trial
costs in 1998. General and administrative expense increased 3.0% to $880,400 for
the third quarter of 1998 compared to $855,000 for the third quarter of 1997
primarily due to the acquisition of VRI. This was partially offset by legal
costs in 1997 associated with the ongoing litigation which was settled in
November 1997.
Non-operating income for the third quarter of 1998 was $144,000
compared to non-operating expense for the third quarter of 1997 of $5,972,100.
Excluding a charge of $6,109,200 relating to the settlement of the Company's
then outstanding litigation in the third quarter of 1997, non-operating income
increased $6,900, or 5.0%, to $144,000 for the third quarter of 1998 compared to
$137,100 for the third quarter of 1997. The increase is primarily due to an
increase in interest income in the third quarter of 1998 compared to 1997
primarily due to higher cash balances due to proceeds from the private placement
in March 1998 combined with the acquisition of VRI on August 21, 1998.
Nine months Ended September 30, 1998 Compared to Nine months Ended
September 30, 1997 -- The Company reported a net loss of $49,484,100, or $1.65
per share, for the nine months ended September 30, 1998, compared to a net loss
of $11,646,600, or $.47 per share, for the nine months ended September 30, 1997.
The net operating loss for the nine months ended September 30, 1998, which
included a charge of $44,630,000 for in-process research and development related
to the acquisitions of VRI, was $50,023,700. Excluding the in-process and
development charge, the net operating loss for the nine months of 1998 would
have been $5,393,700, a decrease of $596,600, or 10.0%, compared to net
operating loss of $5,990,300 for the same period last year.
Operating revenue of $1,082,200 for the nine months ended September 30,
1998 increased $242,100, or 28.8%, compared to $840,100 for the period ended
September 30, 1997. Product development and licensing agreements revenue of
$1,037,700 increased $233,800 or 29.1% for the first nine months of 1998
compared to $803,900 for the same period last year. The increase is primarily
due to $750,000 recognized in 1998 from a nonrefundable option fee associated
with the Company's agreement with Novartis Pharma AG which is being recognized
over the option term combined with $287,700 received in connection with the
Company's SBIR grants. Revenue in 1997 consisted of milestone payments totaling
$650,000 received under the Company's agreement with Astra AB combined with
$153,900 received in connection with the Company's SBIR grants. Product sales
increased $8,300, or 22.9%, to $44,500 for the nine months ended September 30,
1998 compared to $36,200 for the same period last year.
Operating expense of $51,105,900 for the nine months ended September
30, 1998 included a charge of $44,630,000 for in-process research and
development related to the acquisition of VRI. Excluding the in-process research
and development charge, operating expense decreased $354,500, or 5.2%, to
$6,475,900 for the nine months ended September 30, 1998 compared to $6,830,400
for the nine months ended September 30, 1997. Research and development expense
was $4,070,200 for 1998 compared to $4,088,600 for 1997. The decrease in
operating expense is primarily due to a decrease in general and administrative
expense of $339,400, or 12.5%, to $2,385,200 for the first nine months of 1998
compared to $2,724,600 for the same period last year. The decrease in general
and administrative expense is primarily due to legal costs incurred 1997
associated with the ongoing litigation which was settled in November 1997 and
consulting fees incurred in the second quarter of 1997 related to business
development.
Non-operating income for the nine months ended September 30, 1998 was
$539,600 compared to non-operating expense for the nine months ended September
30, 1997 of $5,656,300. Excluding a charge of $6,109,200 relating to the
settlement of the Company's then outstanding litigation in the third quarter of
1997, non-operating income increased $86,700, or 19.1%, to $539,600 for 1998
compared to $452,900 for
11
<PAGE>
1997. Interest income decreased $115,300, or 24.5%, to $355,400 for the nine
months ended September 30, 1998 compared to $470,700 for the same period last
year. The decrease in interest income is primarily due to lower cash balances in
1998 compared to 1997. In May 1998, the Company used cash as collateral for a
$750,000 note due November 15, 1999 issued in connection with a settlement
agreement with its former landlord and the landlord's mortgagee. In accordance
with the settlement agreement, 66,250 shares of the Company's common stock
issued to secure the note were returned to the Company. The common stock was
valued at $165,600 as of October 31, 1997 and its return is included in
non-operating income in 1998.
Liquidity and Capital Resources
At September 30, 1998 the Company's cash, cash equivalents and
marketable securities totaled $15,015,800 compared to $6,436,300 at December 31
1997. The increase is primarily due to cash, cash equivalents and marketable
securities of VRI totaling $13,757,500 acquired on August 21, 1998 combined with
net proceeds of $3,699,900 from the private placement of 2,043,000 shares of the
Company's common stock in March 1998. The increase was partially offset by cash
used in operating activities, which excludes the $44,630,000 non-cash charge for
purchased in-process research and development.
The Company believes that its current cash, cash equivalents, and
marketable securities, net of restricted amounts, together with cash flows from
existing SBIR grants and collaborations, and interest income on invested funds
will be sufficient to meet working capital requirements and fund operations into
2000. The working capital requirements will depend on several factors including,
but not limited to, the progress and costs associated with research and
development programs, preclinical and clinical studies, and the timing and scope
of collaborative arrangements. Because of expected, long-term cash requirements,
the Company anticipates that it will need to take steps to raise additional
capital including, but not limited to, licensing of technology programs with
existing or new collaborative partners, possible business combinations, or
issuance of common stock via private placement and public offering.
THE STATEMENTS IN THE FOLLOWING SECTION INCLUDE "YEAR 2000 READINESS
DISCLOSURE" WITHIN THE MEANING OF THE YEAR 2000 INFORMATION AND DISCLOSURE ACT.
Year 2000
This section contains certain statements that are forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The
Company's Year 2000 compliance, and the eventual effects of the Year 2000 on the
Company may be materially different than currently projected. This may be due
to, among other things, delays in the implementation of the Company's Year 2000
Plan and the failure of key third parties with whom the Company has a
significant business relationship to achieve Year 2000 compliance.
The "Year 2000" issue affects computer systems that have date sensitive
programs that may not properly recognize the year 2000. Systems that do not
properly recognize such information could generate data or cause a system to
fail, resulting in business interruption. The Company is currently developing a
plan to provide assurances that its computer systems are Year 2000 compliant.
Given the relatively small size of the Company's internal systems and the
relatively new hardware, software and operating systems, management does not
anticipate any significant delays in becoming Year 2000 compliant, and expects
full compliance by the end of 1999. Further, management believes at present that
the costs associated with modifications to become Year 2000 compliant will be
immaterial to the Company's continued internal operations.
The Year 2000 issue is expected to affect the systems of various
entities with which the Company interacts, including the Company's research and
development partners, suppliers and vendors. The Company's assessment of third
party anticipated risks and responses to those risks is not complete. There can
be no assurance that the systems of other companies on which the Company's
system rely will be timely converted, or that a failure by another company's
system to be Year 2000 compliant would not have a material adverse affect on the
Company's business, operating results and financial condition.
The Company does not have a contingency plan in the event Year 2000
compliance cannot be achieved in a timely manner. A contingency plan will be
developed upon completion of the Company's Year 2000 compliance assessment.
12
<PAGE>
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
-----------------
There were no material changes since the Company's annual report of
Form 10-K for the year ended December 31, 1997.
Item 2. Changes in Securities
---------------------
None
Item 3. Defaults Upon Senior Securities
-------------------------------
None
Item 4. Submissions of Matters to a Vote of Security Holders
----------------------------------------------------
On August 21, 1998, the Company held a Special Meeting of Stockholders.
The following actions were taken at the meeting:
1. A proposal to approve the issuance of the Company's common stock
and warrants to acquire shares of the Company's common stock
pursuant to an Agreement and Plan of Merger, dated as of May 12,
1998, by and among the Company, TC Merger Corp., a wholly-owned
subsidiary of the Company and Virus Research Institute, Inc.:
14,534,454 shares were voted in favor of the proposal, 872,218
shares were voted against the proposal, 137,123 shares abstained,
and 9,052,218 shares were broker non-votes.
2. A proposal to approve the amendment to the Company's Third Amended
and Restated Certificate of Incorporation to change the name of
the Company to AVANT Immunotherapeutics, Inc.: 23,639,052 shares
were voted in favor of the proposal, 823,374 shares were voted
against the proposal, and 133,587 shares abstained.
3. A proposal to approve an amendment to the Company's Third Amended
and Restated Certificate of Incorporation to increase the number
of authorized shares of the Company's common stock from 50,000,000
to 75,000,000: 23,368,717 shares were voted in favor of the
proposal, 1,077,773 shares were voted against the proposal, and
149,523 shares abstained.
The number of shares issued, outstanding and eligible to vote as of the
record date of July 14, 1998 were 28,466,280. Present was 24,596,013 shares
represented by 254 proxies or 86.4% of the eligible voting shares tabulated.
Item 5. Other Information
-----------------
None.
Item 6. Exhibits and Reports on Form 8-K
--------------------------------
A. Exhibits
None
13
<PAGE>
B. Reports on Form 8-K
The Company reported on Form 8-K, dated August 21, 1998, the
acquisition of Virus Research Institute, Inc. pursuant to an Agreement and Plan
of Merger dated as of May 12, 1998 by and among the Company, TC Merger Corp., a
wholly-owned subsidiary of the Company, and Virus Research Institute, Inc. Under
the terms of the agreement, Virus Research Institute, Inc. became a wholly-owned
subsidiary of the Company.
14
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
AVANT IMMUNOTHERAPEUTICS, INC.
BY: /s/ Una S. Ryan
-------------------------------------
Una S. Ryan, Ph. D.
President and Chief Executive Officer
Dated: November 16, 1998
-----------------
15
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
condensed financial statements of AVANT Immunotherapeutics, Inc. for the Nine
Months Ended September 30, 1998 and is qualified in its entirety by reference to
such financial statements.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> SEP-30-1998
<CASH> 7,150,000
<SECURITIES> 7,865,300
<RECEIVABLES> 10,600
<ALLOWANCES> 0
<INVENTORY> 9,200
<CURRENT-ASSETS> 16,317,800
<PP&E> 5,248,700
<DEPRECIATION> (4,182,700)
<TOTAL-ASSETS> 25,146,500
<CURRENT-LIABILITIES> 2,755,200
<BONDS> 0
0
0
<COMMON> 42,500
<OTHER-SE> 21,010,200
<TOTAL-LIABILITY-AND-EQUITY> 25,146,500
<SALES> 44,500
<TOTAL-REVENUES> 1,082,200
<CGS> 20,500
<TOTAL-COSTS> 51,085,400
<OTHER-EXPENSES> (184,200)
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (355,400)
<INCOME-PRETAX> (49,484,100)
<INCOME-TAX> 0
<INCOME-CONTINUING> (49,484,100)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (49,484,100)
<EPS-PRIMARY> (1.65)
<EPS-DILUTED> (1.65)
</TABLE>
